XERS — Xeris Biopharma Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $1.49bn
- $1.65bn
- $203.07m
- 45
- 39
- 97
- 64
Annual cashflow statement for Xeris Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -91.1 | -123 | -94.7 | -62.3 | -54.8 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 11.9 | 13.5 | 16.1 | 10.4 | 16.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.8 | 11.9 | -35.1 | -6.29 | -8.82 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -80.6 | -95.5 | -103 | -47 | -37 |
| Capital Expenditures | -0.377 | -1.08 | -0.524 | -2.26 | -0.868 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -27 | 99 | 35 | -3.74 | 5.75 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -27.4 | 98 | 34.5 | -6 | 4.88 |
| Financing Cash Flow Items | -10.3 | -0.054 | -4.88 | -1.19 | -11.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 126 | 27.2 | 127 | -1.61 | 36.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 18.1 | 29.7 | 59 | -54.6 | 4.07 |